Ovarian Cancer Hemoscope Trial
Active, not recruiting
- Conditions
- Ovarian Neoplasms
- Registration Number
- NCT02811224
- Lead Sponsor
- Scripps Translational Science Institute
- Brief Summary
This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Case Group
- Patients with ovarian cancer undergoing surgery (all stages)
- Over 18 years old
Control Group
- Patients with a benign gynecological condition undergoing surgery
- Over 18 years old
Exclusion Criteria
- Previous cancer diagnosis (all)
- Radiation therapy before surgical treatment
- Bone marrow transplant
- Chemotherapy before surgical treatment
- Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sensitivity of an assay that detects circulating tumor DNA 3 years
- Secondary Outcome Measures
Name Time Method